Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson's disease.

Kahana M, Weizman A, Gabay M, Loboda Y, Segal-Gavish H, Gavish A, Barhum Y, Offen D, Finberg J, Allon N, Gavish M.

Mol Psychiatry. 2020 May 5. doi: 10.1038/s41380-020-0742-4

A novel specific PERK activator reduces toxicity and extends survival in Huntington's disease models.

Ganz J, Shacham T, Kramer M, Shenkman M, Eiger H, Weinberg N, Iancovici O, Roy S, Simhaev L, Da'adoosh B, Engel H, Perets N, Barhum Y, Portnoy M, Offen D, Lederkremer GZ.

Sci Rep. 2020 Apr 23;10(1):6875. doi: 10.1038/s41598-020-63899-4.

Prediction of synonymous corrections by the BE-FF computational tool expands the targeting scope of base editing.

Rabinowitz R, Abadi S, Almog S, Offen D.

Nucleic Acids Res. 2020 Apr 7. pii: gkaa215. doi: 10.1093/nar/gkaa215. 

Caspase-6 Knockout in the 5xFAD Model of Alzheimer's Disease Reveals Favorable Outcome on Memory and Neurological Hallmarks.

Angel A, Volkman R, Royal TG, Offen D.

Int J Mol Sci. 2020 Feb 9;21(3). pii: E1144. doi: 10.3390/ijms21031144.

Genes to treat excitotoxicity ameliorate the symptoms of the disease in mice models of multiple system atrophy.

Glat MJ, Stefanova N, Wenning GK, Offen D.

J Neural Transm (Vienna). 2020 Feb;127(2):205-212. doi: 10.1007/s00702-020-02158-2. Epub 2020 Feb 17.


©2017 by Dani Offen’s Laboratory for Translational Neuroscience. Proudly created with Wix.com